API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
The agreement grants Define Biotech the exclusive right to distribute maitake mushroom, rich in bioactive polysaccharides, especially beta-glucans, as new dietary supplement in China and Taiwan in exchange for the commitment of the new product over the three-year period.
Lead Product(s): Beta Glucan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ABVC BioPharma
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Agreement December 09, 2021
Details:
The effect of oat beta glucan on the study primary endpoint is change in LDL-C, and some positive findings observed with different parameters, there were dosage-related responses in weight and body-mass index at 12 weeks but they also did not reach statistical significance.
Lead Product(s): Beta Glucan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2021
Details:
Under the collaboration, pre-clinical studies using methods developed by the Angiogenesis Foundation will be conducted to characterize the in vivo bioactivity of Ceapro’s oat-derived bioactive products, beta glucan and avenanthramides.
Lead Product(s): Beta Glucan
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Angiogenesis Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 23, 2021